Nanobiotix S.A. (EPA:NANO)

Market Cap	1.59B +896.8%
Revenue (ttm)	32.59M
Net Income	-23.96M
EPS	-0.50
Shares Out	50.71M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	224,148
Open	32.06
Previous Close	31.26
Day's Range	30.00 - 32.36
52-Week Range	3.66 - 47.66
Beta	0.58
Analysts	Strong Buy
Price Target	46.00 (+52.62%)
Earnings Date	Jun 5, 2026

About Nanobiotix

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Th...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 100
• Stock Exchange: Euronext Paris
• Ticker Symbol: NANO

Analyst Summary

According to 5 analysts, the average rating for NANO stock is "Strong Buy." The 12-month stock price target is €46.00, which is an increase of 52.62% from the latest price.

Price Target

€46.00

(52.62% upside)

Analyst Consensus: Strong Buy